Having invested $84 million almost a year and a half ago to launch a drug discovery collaboration with GeneProt, Novartis might not seem the most likely big pharma candidate to establish a strong and growing internal proteomics research program of its own. After all, the deal with GeneProt is still most likely the largest of its kind, dwarfing Oxford GlycoScience’s cumulative $22.5 million deal with Pfizer, and represents a massive capital and human resource investment for GeneProt’s 110 Geneva-based employees.